<?xml version="1.0" encoding="UTF-8"?>
<p id="p0015">Measles is highly communicable, with greater than 90% secondary attack rates among susceptible persons. It is still a public health problem in many developing countries, particularly in parts of Asia and Africa. According to the WHO, more than 20 million people are affected by measles each year with more than 95% of measles deaths occur in developing countries especially with more than half of measles deaths occur in sub-Saharan Africa and this burden accounted for 15% of all under-five mortality (
 <xref rid="bib28" ref-type="bibr">O (World Health Organiz, 2012</xref>). Measles vaccine is the best way to reduce the risk of contracting measles. It is safe, effective and inexpensive. Unvaccinated young children and pregnant women are at highest risk of measles and its complications, including death. Immunity conferred by vaccination against measles has been shown to persist for at least 20 years and is generally thought to be life-long for most individuals. Measles vaccine efficacy is expected to be 85% at 9â€“11 months of age and increases to 97% after a second dose given at greater than 12 months (
 <xref rid="bib28" ref-type="bibr">O (World Health Organiz, 2012</xref>).
</p>
